Friday, November 28th 2014_Our Publisher Pick is Aethlon Medical (AEMD), An Ebola Patiient Treated With The Company’s Hemopurifier® Therapy Was Unconscious And Suffering From Multiple Organ Failure Has Fully Recovered, Time Magazine Just Named Aethlon Medical (AEMD) Hemopurifier® One Of The Best 25 Inventions Of 2014




Many of our publisher picks rise 100%, 200% or more once they hit the front page of our blog. Get some, sit back and enjoy the ride! Recent big winners include BSTO, XCLL, GRLT HHSE and UAPC

Follow Sierra on Twitter To Get Our Next Publisher Pick~~Follow Sierra on Twitter

Our Ebola Publisher Pick is Aethlon Medical (AEMD) 

Here is why Sierra’s publisher has initiated a long position in AEMD, the last 6 weeks have provided positive scientific data and successful human results that are nothing short of miraculous. There is little doubt that shares of Aethlon Medical (AEMD) will soon be trading conservatively in the $1 to $5 range!


November 26th 2014: Aethlon Medical (AEMD) announced the first shipment of Hemopurifier® therapy as a candidate to treat future Ebola virus infections in the United States. The company disclosed that four Hemopurifiers have been shipped to the Biocontainment Unit at the Nebraska Medical Center (NMC) in Omaha as a therapeutic option to be stockpiled for Ebola patients that may be treated at the NMC.  Aethlon further disclosed that it has provided onsite training to NMC clinical personnel related to the implementation of Hemopurifier® therapy within the dialysis infrastructure already located at the center

November 25th 2014: Ebola patient who received Hemopurifier® therapy has been reported to have been discharged from Frankfurt University Hospital in Germany. The patient was a Ugandan physician, who became infected with Ebola in Sierra Leone where he was treating other Ebola patients. The Aethlon Hemopurifier® is a first-in-class bio-filtration device that targets the rapid elimination of viruses and immunosuppressive proteins from the circulatory system of infected individuals.  At the time Hemopurifier® therapy was administered to the Ugandan physician, he was unconscious and suffered from multiple organ failure.  His viral load prior to the administration of a single 6.5-hour Hemopurifier® treatment was measured at 400,000 virus copies per milliliter of blood (copies/ml). Post-treatment viral load was measured at 1,000 copies/ml and never again rose above that level. Viral load became undetectable five days after therapy.  The treatment was well tolerated with no adverse events reported.  Additionally, a post-treatment elution protocol verified that 242 million Ebola viruses were captured within the Hemopurifier® during treatment

November 21st 2014: TIME Magazine names Aethlon Medical (AEMD) Hemopurifier®  one of the best 25 inventions of 2014



November 19th 2014: Aethlon Medical (AEMD) disclosed today that it will provide Hemopurifier® therapy under FDA expanded access “emergency use” provisions to support requests from qualified physicians and institutes that may seek to treat ebola virus infection in the United States. Expanded access “emergency use” of an investigational device does not require advance FDA approval for life threatening circumstances for which an alternative therapy is not available. At present, no antiviral therapy or vaccine has proven to be effective against Ebola virus infection in humans

Even before the current Ebola outbreak Aethlon Medical (AEMD) was a great buy with it’s Hemopurifier® a first-in-class bio-filtration device that targets the rapid elimination of viruses and immunosuppressive proteins from the circulatory system of infected individuals advance the device as a broad-spectrum countermeasure against pandemic threats, including Ebola and chronic viral pathogens such as HIV and Hepatitis C (HCV). 

Hemopurifier therapy is now being used to treat a patient with advanced Ebola, while all wish for the patient’s full recovery huge potential revenue streams await AEMD in other Hemopurifier therapy applications. It is worth highlighting that Hemopurifier therapy has been successfully administered in approximately one hundred treatment experiences in health compromised HIV and HCV infected individuals and that preparing to initiate U.S. clinical studies of Hemopurifier therapy based on the United States Food and Drug Administration’s (FDA) approval of an Investigational Device Exemption (IDE) that was previously submitted by the Company. (Note: The patient being treated with Hemopurifier® therapy has now fully recovered, see above official press release dated November 25th 2014)

October 14th 2014: Aethlon Medical (AEMD) announced today the first use of Hemopurifier® therapy on a patient infected with Ebola virus.  The treatment was administered to a Ugandan doctor at the Frankfurt University Hospital in Germany.  The patient, who is also a World Health Organization (WHO) worker, contracted the virus in Sierra Leone. (Note: The patient being treated with Hemopurifier® therapy has now fully recovered, see above official press release dated November 25th 2014)

To date, Hemopurifier therapy has been successfully administered in approximately one hundred treatment experiences in health compromised HIV and HCV infected individuals. These studies were conducted at the Apollo Hospital, Fortis Hospital, Sigma New Life Hospital, and the Medanta Medicity Institute, all located in India.  In vitro validation studies that demonstrated the ability of the Hemopurifier to capture Zaire and other strains of ebola virus were conducted by researchers at the United States Army Medical Research Institute for Infectious Diseases (USAMRIID) and the United States Centers for Disease Control and Prevention (CDC)

Aethlon further disclosed that it is preparing to initiate U.S. clinical studies of Hemopurifier therapy based on the United States Food and Drug Administration’s (FDA) approval of an Investigational Device Exemption (IDE) that was previously submitted by the Company.  The study will contribute safety data to advance the device as a broad-spectrum countermeasure against pandemic threats, including ebola and chronic viral pathogens such as HIV and Hepatitis C (HCV)

October 14 2014: Zacks Small Cap Research stated “Ebola could offer significant opportunity for AEMD….the in vitro studies indicated that Hemopurifier captured a significant amount of the Ebola virus in just one hour. Aethlon is also looking to offer Hemopurifier treatment in the U.S. for Ebola.  The company recently noted that they reached out to FDA to help determine if there may be an opportunity to consider use of Hemopurifier with patients infected with Ebola from the current outbreak.”

With over 1 million visitors to our blog and thousands of visitors daily, Sierra World Equity Review will be giving MASSIVE MULTIPLE DAY targeted audience exposure to our latest Publisher Pick Aethlon Medical (AEMD)

Follow Sierra on Twitter To Get Our Next Publisher Pick~~Follow Sierra on Twitter

About Sierra World Equity Review

Providing special focus to speculative predictions on upcoming stock news including but not limited to FDA drug approvals and clinical trials to potential joint ventures, mergers, acquisitions and lawsuit settlements. Sierra World Equity Review covers all sectors from Biotech to Oil stocks, Gold stocks, Penny stocks , the OTC as well as the S&P, Nasdaq, Dow Jones and Amex. We also issue short term daily buy or sell ratings with 5 day price targets for stocks in all industries across all markets. Every day we present our publisher’s pick where we profile a stock that our publisher has taken a position in, we believe that the stock is extremely undervalued with potential for significant percentage gains.

Sierra World Equity Review and it’s publisher have not been compensated to promote Aethlon Medical (AEMD)  but do hold a long position in the stock. We are not affiliated with any executives, owners, brokers, promoters, analysts, or trading groups. The publisher of Sierra World Equity Review is not a registered investment adviser, before making a purchase or sale of any securities featured on this site, we strongly recommend consultation with a registered securities representative. Please remember to do your own due diligence in regards to any stocks that appear on our websites, please read our disclaimer and privacy policy below.

disclaimer and privacy policy